Spatial colocalization of neoantigen-expressing tumor cells and cognate T cells in cancer 2309241

A Adi Nagler A Amit Sud J Jack Ghannam (Dana-Farber Cancer Institute) L Lucas Pomerance C Camila Robles-Oteiza (Dana-Farber Cancer Institute) A Alexander Afeyan (Dana-Farber Cancer Institute) J Jackson Weir A Andrew Russell (Broad institute) W Wesley Lu (2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA) M McKayla Van-Orden (Dana-Farber Cancer Institute) A Andrea Sonnenholzner (Dana-Farber Cancer Institute) G Giovanni Marrero (Broad institute) Q Qiyu Gong V Vipin Kumar M MacLean Sellars (Dana-Farber Cancer Institute) C Charles Yoon (Brigham and Women’s Hospital) D David Reardon (Dana Farber Cancer Institute) T Toni Choueiri (1Dana-Farber Cancer Institute, Boston, United States) P Patrick Ott (Dana-Farber Cancer Institute) D David Braun (Section of Medical Oncology, Department of Medicine Yale Cancer Center Yale University New Haven Connecticut USA) G Giacomo Oliveira S Shuqiang Li K Kenneth Livak (5Dana-Farber Cancer Institute, Translational Immunogenomics Lab, Boston, United States) N Nir Hacohen F Fei Chen C Catherine Wu (1Dana Farber Cancer Institute, Boston, United States)

Abstract

Abstract Introduction Tumor neoantigens have emerged as promising candidates for personalized immunotherapies, however, confirming their presentation and immunogenicity remains challenging due to low neoantigen expression and limited detection sensitivity. Moreover, the spatial organization of neoantigen-specific T cell clones relative to their target tumor cells and other cell types within the tumor microenvironment remains incompletely defined due to technological limitations. To bridge this gap, we developed Slide-GoTags. Methods Slide-GoTags integrates single-nucleus spatial transcriptomics with targeted genotyping and TCR sequencing from a single 20 µm tissue section. Slide-tags spatial barcoding and the 10x Genomics 5’ droplet-based platform are followed by targeted RNase H—dependent PCR and long-read sequencing, enabling genotypes and TCR repertoires to be linked to gene expression profiles and spatial coordinates via shared cell barcodes. Results Slide-GoTags was applied to murine and human tumors, revealing colocalization of clonally expanded, neoantigen-specific T cells with tumor cells expressing their cognate neoantigen, validated by known neoantigen-TCR pairs. T cell functional state and clonotype avidity were linked to neoantigen proximity. Moreover, we identified IFN-γ—rich immunogenic niches consistently enriched for neoantigen-specific progenitor-exhausted T cells, marked by enhanced local T cell activation, clonal expansion, and immune-modulatory interactions with antigen-presenting cells within the TME. Spatially resolved receptor—ligand analysis revealed co-stimulatory and inhibitory interactions that shape immune engagement and regulation within these niches. Conclusion In this study, we define the spatial architecture of neoantigen directed T cell immunity shaped by proximity to neoantigen expressing tumor cells, TCR avidity, and receptor-ligand interactions within tumors, providing a framework for spatially informed TCR deorphanization and the development of personalized T cell therapy. Funding Source This work was supported in part by the NIH/NCI (CA276865), the Mark Foundation for Cancer Research Endeavor Award, the Dana-Farber/Harvard Cancer Center Kidney SPORE (P50CA101942), and the Dana-Farber/Harvard Cancer Center Support Grant (P30CA006516). A.N Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (26)

A

Adi Nagler

A

Amit Sud

J

Jack Ghannam

Dana-Farber Cancer Institute

L

Lucas Pomerance

C

Camila Robles-Oteiza

Dana-Farber Cancer Institute

A

Alexander Afeyan

Dana-Farber Cancer Institute

J

Jackson Weir

A

Andrew Russell

Broad institute

W

Wesley Lu

2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

M

McKayla Van-Orden

Dana-Farber Cancer Institute

A

Andrea Sonnenholzner

Dana-Farber Cancer Institute

G

Giovanni Marrero

Broad institute

Q

Qiyu Gong

V

Vipin Kumar

M

MacLean Sellars

Dana-Farber Cancer Institute

C

Charles Yoon

Brigham and Women’s Hospital

D

David Reardon

Dana Farber Cancer Institute

T

Toni Choueiri

1Dana-Farber Cancer Institute, Boston, United States

P

Patrick Ott

Dana-Farber Cancer Institute

D

David Braun

Section of Medical Oncology, Department of Medicine Yale Cancer Center Yale University New Haven Connecticut USA

G

Giacomo Oliveira

S

Shuqiang Li

K

Kenneth Livak

5Dana-Farber Cancer Institute, Translational Immunogenomics Lab, Boston, United States

N

Nir Hacohen

F

Fei Chen

C

Catherine Wu

1Dana Farber Cancer Institute, Boston, United States